IRIS
DI GIACOMO, ANNA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.124
EU - Europa 4.427
AS - Asia 2.022
SA - Sud America 466
AF - Africa 34
OC - Oceania 10
Totale 12.083
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.084
IE - Irlanda 1.032
IT - Italia 1.026
SG - Singapore 813
GB - Regno Unito 582
RU - Federazione Russa 530
CN - Cina 486
BR - Brasile 432
HK - Hong Kong 354
DE - Germania 275
SE - Svezia 270
FR - Francia 233
UA - Ucraina 174
VN - Vietnam 106
FI - Finlandia 91
IN - India 76
ES - Italia 68
KR - Corea 60
NL - Olanda 44
AT - Austria 36
CA - Canada 17
TR - Turchia 16
ZA - Sudafrica 16
AR - Argentina 15
MX - Messico 13
PL - Polonia 12
AZ - Azerbaigian 11
BD - Bangladesh 10
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
AU - Australia 8
PK - Pakistan 8
SA - Arabia Saudita 8
BE - Belgio 7
CH - Svizzera 7
EC - Ecuador 7
IQ - Iraq 6
KG - Kirghizistan 6
NO - Norvegia 6
AL - Albania 5
JP - Giappone 5
PH - Filippine 5
EE - Estonia 4
TN - Tunisia 4
AM - Armenia 3
BG - Bulgaria 3
BO - Bolivia 3
CI - Costa d'Avorio 3
DK - Danimarca 3
EG - Egitto 3
GR - Grecia 3
IR - Iran 3
JO - Giordania 3
LK - Sri Lanka 3
LT - Lituania 3
MA - Marocco 3
PT - Portogallo 3
VE - Venezuela 3
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
GE - Georgia 2
HR - Croazia 2
ID - Indonesia 2
JM - Giamaica 2
KE - Kenya 2
KH - Cambogia 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
MY - Malesia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TW - Taiwan 2
BH - Bahrain 1
CL - Cile 1
CO - Colombia 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
IM - Isola di Man 1
LV - Lettonia 1
MD - Moldavia 1
NP - Nepal 1
PY - Paraguay 1
QA - Qatar 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 12.083
Salva come PNG Salva come JPEG
Città #
Dublin 1.027
Fairfield 817
Santa Clara 527
Southend 453
Woodbridge 399
Singapore 394
Ashburn 389
Hong Kong 351
Seattle 331
Houston 304
Cambridge 299
Wilmington 289
Siena 266
Beijing 246
Princeton 170
Jacksonville 157
Ann Arbor 134
Chandler 120
Milan 111
Dong Ket 101
San Mateo 84
Florence 82
Moscow 75
Shanghai 73
Dearborn 67
New York 62
Málaga 57
Rome 55
Seoul 52
Helsinki 51
Bengaluru 49
San Diego 47
Nuremberg 45
London 30
Los Angeles 28
Lauterbourg 25
Nanjing 25
San Francisco 24
Munich 23
Portsmouth 23
Vienna 22
São Paulo 19
Bologna 18
Lappeenranta 18
Borgo San Lorenzo 17
Cascina 16
Düsseldorf 16
Fremont 16
Frankfurt am Main 15
Turku 15
Boardman 14
Belo Horizonte 13
Amsterdam 12
Empoli 12
Redwood City 12
Baku 11
Brooklyn 11
Delhi 11
Perugia 11
Sesto Fiorentino 11
The Dalles 11
Nanchang 10
Naples 10
Norwalk 10
Hefei 9
Montevarchi 9
Palermo 9
Tashkent 9
Toronto 9
Council Bluffs 8
Guangzhou 8
Kilburn 8
Padova 8
Asciano 7
Bari 7
Brasília 7
Brussels 7
Kunming 7
Lambeth 7
Lucca 7
Phoenix 7
Rio de Janeiro 7
Stockholm 7
Venezia 7
Warsaw 7
Johannesburg 6
Marano Vicentino 6
Orbetello 6
Riyadh 6
Tianjin 6
Uberlândia 6
Yongsan-gu 6
Campinas 5
Catania 5
Chicago 5
Guayaquil 5
Hounslow 5
Islington 5
Mexico City 5
Natal 5
Totale 8.436
Salva come PNG Salva come JPEG
Nome #
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 237
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 237
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 211
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 195
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 195
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 188
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. 184
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 178
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 162
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 154
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 150
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 147
Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/ mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study 142
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 134
The italian experience on the feasibility and safety of ipilmumab therapy in pretracted metastatic melanoma patients 133
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 133
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 129
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 128
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 126
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 124
Immunotherapy targeting immune check-point(s) in brain metastases 119
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 119
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 118
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 117
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis 116
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications 115
Predictors of responses to immune checkpoint blockade in advanced melanoma 113
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 112
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab 112
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 112
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells 111
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 110
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? 106
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 105
A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial 105
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond 103
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients 102
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 100
Challenges in lung cancer therapy during the COVID-19 pandemic 100
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID 97
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 97
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 97
Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? 96
Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 96
null 95
Epigenetics meets immune checkpoints 94
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study 94
The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients 93
Ipilmumab in pretreated metastatic uveal melanoma patiens; safety and clinical efficacy 92
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial 92
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients 90
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 90
Nivolumab plus ipilimumab in melanoma brain metastases 90
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 90
Long-term follow-up of a papillary tumor of the pineal region: addendum to a case report 89
Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial 89
Back to simplicity: A four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients 89
null 87
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy 87
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications 85
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients 85
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab 85
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma 84
Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications 83
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches 79
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 79
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 79
Can epigenetics have a clinical impact in the treatment of melanoma? 79
A novel microRNA signature for the detection of melanoma by liquid biopsy 78
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 78
Dietary compounds and cutaneous malignant melanoma: Recent advances from a biological perspective 78
null 75
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 73
The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases 72
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial 71
Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial 71
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study 70
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: A case report 70
Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop” 69
Long term survival and immunological correlates in metastatic melanoma treated with IPILIMUMAB 10 mgs within an expanded access program 69
The cost of unresectable stage III or stage IV melanoma in Italy 69
Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy 69
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma 69
SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome 69
Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix 69
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma 68
The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors 67
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma 67
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study 67
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial 67
Immunotherapy of brain metastases: breaking a "dogma" 66
Effects of molecular heterogeneity on survival of patients with BRAFV600-mutated melanoma treated with vemurafenib with or without cobimetinib in the coBRIM study 65
Update on the role of ipilimumab in melanoma and first data on new combination therapies 65
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma 65
Health-related quality of life in patients with fully resected BRAFV600 mutation–positive melanoma receiving adjuvant vemurafenib 65
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 65
Epigenetic immunomodulation of hematopoietic malignancies 64
Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases 64
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients 62
From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma 62
Totale 10.162
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.515
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.515
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020129 0 0 0 0 0 0 0 0 0 0 0 129
2020/20212.017 48 173 100 115 427 251 71 309 80 165 59 219
2021/2022989 43 87 91 20 18 65 34 42 74 137 123 255
2022/20231.378 112 90 223 118 58 246 44 71 96 60 220 40
2023/20241.738 67 66 161 63 49 413 581 62 44 27 42 163
2024/20254.210 127 153 333 244 478 287 144 180 503 332 482 947
Totale 12.627